STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] InspireMD, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rosalind Advisors, related funds and principals report material holdings in InspireMD (NSPR). The filing shows aggregate beneficial positions reported as 10,987,104 shares for several Reporting Persons, which the filing presents as approximately 9.4% of the class based on the S-3 share count and other per-entity percentages (Rosalind Master Fund L.P. 9.485,697 shares / 8.4%; Rosalind Opportunities Fund I L.P. 1,501,407 shares / 0.9%).

The reported totals include both currently outstanding common shares and shares issuable upon exercise of warrants (for example, Rosalind Advisors reports 3,905,743 common shares plus 7,081,361 shares issuable on warrants). The filing also discloses blocker provisions that prevent exercise of warrants to the extent doing so would push beneficial ownership above 9.99%, so the practical exercisable interest is lower than the raw issuable amount. The filing includes a certification that the holdings are held in the ordinary course of business and not for the purpose of changing control.

Positive

  • Material disclosure of beneficial ownership above 5% by Rosalind entities and named principals, meeting SEC reporting standards
  • Detailed breakdown between currently held common shares and shares issuable on warrants, improving investor transparency
  • Certification states holdings are in the ordinary course of business and not for the purpose of changing control

Negative

  • Blocker provisions prevent exercise of warrants beyond 9.99%, limiting the practical increase in ownership despite large issuable amounts
  • Inconsistent bases for percent calculations are cited (different outstanding share counts from an S-3 and the issuer's 10-K), creating ambiguity about the exact percentage ownership

Insights

TL;DR: A disclosed stake near 9.4% is material and includes significant warrant exposure, but blockers limit near-term dilution.

The Schedule 13G/A shows the Rosalind group and named principals reporting beneficial positions that cross the 5% materiality threshold, with several reporting persons listing 10,987,104 shares (9.4%). Importantly, the reported position is a mix of issued shares and 7+ million shares issuable on warrants for some entities. Warrant blocker provisions restricting exercise above 9.99% mean the effective, exercisable ownership is constrained, reducing immediate dilution or control shifts. For analysts, the filing is material as it signals a significant investor position and potential future conversion dynamics, but the blocker materially limits short-term upside from warrant exercises.

TL;DR: Disclosure is thorough on holdings and intent; blocker language and inconsistent share bases create governance and clarity issues for investors.

The filing provides clear identification of reporting parties, vote/dispositive power allocations, and a certification that holdings are not intended to change control. That transparency is positive for governance. However, the filing references different outstanding share counts (a figure tied to an S-3 and a figure tied to the issuer's 10-K) when computing percentages, creating ambiguity about the precise ownership percentage investors should use. The existence of blocker provisions limits immediate conversion rights, which is governance-relevant because it constrains potential influence from warrant conversion despite large issuable amounts.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The percentage set forth in Row 11 of the cover page for each Reporting Person is based upon 41,720,662 shares of common stock outstanding of the Issuer as of August 1, 2025, in accordance with the S-3 filed on August 1st. However, as more fully described in Item 4, the securities reported in rows 6, 8, and 9 show the number of shares of Common Stock that would be issuable upon exercise of such reported securities and do not give effect to blocker provisions. Therefore, the actual number of shares of Common Stock beneficially owned by such Reporting Person, after giving effect to such blockers, is less than the number of securities reported in rows 6, 8, and 9. (6) 3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,905,743 shares of Common Stock 7,081,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)3,508,336 shares of Common Stock 5,977,361 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G




Comment for Type of Reporting Person: (6)397,407 shares of Common Stock 1,104,000 shares of Common Stock issuable upon exercise of warrants


SCHEDULE 13G



Rosalind Advisors, Inc.
Signature:Steven Salamon
Name/Title:President
Date:08/11/2025
SALAMON STEVEN A J
Signature:Steven Salamon
Name/Title:Steven Salamon
Date:08/11/2025
Aharon Gil
Signature:Gil Aharon
Name/Title:Gil Aharon
Date:08/11/2025
Rosalind Master Fund L.P.
Signature:Mike McDonald
Name/Title:Director, Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund)
Date:08/11/2025
Rosalind Opportunities Fund I L.P.
Signature:Steven Salamon
Name/Title:Director, Rosalind Opportunities Fund I GP. Inc. (as General Partners to Rosalind Opportunities Fund I)
Date:08/11/2025

FAQ

What stake does Rosalind Advisors report in InspireMD (NSPR)?

Rosalind Advisors reports an aggregate beneficial position of 10,987,104 shares, presented as approximately 9.4% of the class (this total includes both currently outstanding shares and shares issuable upon exercise of warrants).

How many shares and warrants are included in Rosalind's reported position?

The filing discloses specific components: for example, Rosalind Advisors lists 3,905,743 common shares plus 7,081,361 shares issuable on warrants as part of its reported total.

Do the reported warrants allow immediate conversion to increase ownership?

No. The filing states blocker provisions9.99%, so many issuable warrants cannot be exercised currently.

Which entities and individuals are the reporting persons in this filing?

Reporting persons include Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., and principals Steven Salamon and Gilad Aharon.

Are these holdings reported as intended to change control of InspireMD (NSPR)?

The filing includes a certification stating the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer, aside from nomination activities under the cited rule.

Why do percentage figures in the filing differ?

The filing references different outstanding share counts when computing percentages (a share count from an S-3 and a share count from the issuer's 10-K), which explains the differing percentage presentations.
Inspiremd

NASDAQ:NSPR

NSPR Rankings

NSPR Latest News

NSPR Latest SEC Filings

NSPR Stock Data

84.74M
33.05M
22.45%
40.55%
0.31%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MIAMI